StockNews.com Upgrades Omnicell (NASDAQ:OMCL) to Buy

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a research report report published on Friday.

OMCL has been the topic of several other research reports. Bank of America cut their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Benchmark reiterated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company decreased their price target on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and an average price target of $50.67.

Omnicell Trading Down 0.8 %

Shares of NASDAQ:OMCL opened at $30.96 on Friday. The company has a market cap of $1.45 billion, a PE ratio of 114.67, a P/E/G ratio of 7.53 and a beta of 0.78. The company’s 50 day moving average is $34.32 and its two-hundred day moving average is $40.84. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Shaker Investments LLC OH purchased a new stake in Omnicell in the 4th quarter valued at approximately $550,000. Empowered Funds LLC acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $388,000. Exchange Traded Concepts LLC boosted its stake in shares of Omnicell by 6.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock valued at $14,232,000 after buying an additional 20,031 shares in the last quarter. SG Americas Securities LLC grew its holdings in Omnicell by 56.5% during the fourth quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock worth $1,752,000 after acquiring an additional 14,202 shares during the period. Finally, CIBC Asset Management Inc purchased a new position in Omnicell in the fourth quarter worth $201,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.